← Back to Search

Monoclonal Antibodies

Combination Therapy for Mantle Cell Lymphoma

Phase 1 & 2
Recruiting
Led By Tycel J Phillips
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline up until 30 days after last dose of study drug
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a combo of drugs to treat mantle cell lymphoma, to stop cancer growth & help the immune system kill cancer cells.

Who is the study for?
This trial is for adults aged 18-80 with newly diagnosed, high-risk mantle cell lymphoma who haven't had cancer treatment before. Participants must be able to swallow pills, have certain blood counts and organ function levels, and agree to use effective birth control. People can't join if they've used certain drugs recently, have a history of other cancers or significant heart disease, active infections including hepatitis B/C or HIV, are pregnant/breastfeeding, or have CNS lymphoma.
What is being tested?
The trial tests the combination of glofitamab (a monoclonal antibody), venetoclax (BCL-2 inhibitor), and lenalidomide in treating high-risk mantle cell lymphoma. It aims to see if this drug combo is safe and more effective than current treatments by stopping cancer cells from growing.
What are the potential side effects?
Potential side effects include reactions related to the immune system's response to monoclonal antibodies like glofitamab and obinutuzumab; low blood counts due to bone marrow suppression; digestive issues from lenalidomide; fatigue; increased risk of infection; liver problems; and possible allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline up until 30 days after last dose of study drug
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline up until 30 days after last dose of study drug for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of dose limiting toxicity
Secondary study objectives
Best overall response
Incidence of adverse events of special interest

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (venetoclax, glofitamab, lenalidomide)Experimental Treatment9 Interventions
Patients receive venetoclax PO, obinutuzumab IV, glofitamab IV, and lenalidomide IV on study. Patients undergo bone marrow biopsy, blood sample collection, and CT scan and/or PET scan throughout the study. Patients may undergo tumor biopsy throughout the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Obinutuzumab
2014
Completed Phase 3
~3470
Glofitamab
2021
Completed Phase 1
~60
Lenalidomide
2005
Completed Phase 3
~2240
Computed Tomography
2017
Completed Phase 2
~2740
Bone Marrow Biopsy
2021
Completed Phase 3
~230
Biopsy
2014
Completed Phase 4
~1090
Biospecimen Collection
2004
Completed Phase 3
~2020
Positron Emission Tomography
2011
Completed Phase 2
~2200
Venetoclax
2019
Completed Phase 3
~2200

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,920 Previous Clinical Trials
41,017,066 Total Patients Enrolled
City of Hope Medical CenterLead Sponsor
602 Previous Clinical Trials
1,923,530 Total Patients Enrolled
Tycel J PhillipsPrincipal InvestigatorCity of Hope Medical Center
1 Previous Clinical Trials
10 Total Patients Enrolled

Media Library

Glofitamab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05861050 — Phase 1 & 2
Mantle Cell Lymphoma Research Study Groups: Treatment (venetoclax, glofitamab, lenalidomide)
Mantle Cell Lymphoma Clinical Trial 2023: Glofitamab Highlights & Side Effects. Trial Name: NCT05861050 — Phase 1 & 2
Glofitamab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05861050 — Phase 1 & 2
~24 spots leftby Feb 2026